Versican Plus Bb Oral
Active substance
ATC code
Species
Dogs.
Indications
For active immunisation of dogs of 8 weeks of age or older to reduce clinical signs following infection with Bordetella bronchiseptica.
Onset of immunity: 7 days.
Duration of immunity: 1 year.
Dose to be administered and administration route
Oral use.
Method and route of administration:
Grip the lyophilisate vial with your fingers and position your thumb directly under the embossed triangle on the vial cap.
Using your thumb, push the vial cap upwards from underneath the embossed triangle to allow access to the rubber stopper.
Do not remove the vial
cap or aluminium collar as they are not designed to be removed for use with a syringe and needle.
Aseptically reconstitute
the lyophilisate with the solvent. The reconstituted veterinary medicinal product should be an orange to yellow turbid liquid which might contain a loose resuspendable sediment.
Shake the veterinary medicinal product well after reconstitution.
Withdraw the liquid with the syringe and remove the needle. The veterinary medicinal product should then be used immediately.
The head of the dog
should be held with the nose pointing upwards and mouth open. Administer the entire 1 ml dose into the buccal pouch (between the teeth and the buccal mucosa).
Primary vaccination scheme:
Vaccination with 1 dose of 1 ml per dog from the age of 8 weeks.
Re-vaccination scheme:
One dose annually.
Adverse reactions
Dogs:
|
Rare (1 to 10 animals / 10,000 animals treated): |
Ocular discharge1 |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Diarrhoea2, Vomiting2 Hypersensitivity reaction (e.g. anaphylaxis, dyspnoea and/or tachypnoea, facial oedema, urticaria)3 Nasal discharge2, Cough2 Lethargy2 |
1Mild.
2Mild, for up to 14 days after vaccination.
3If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.
